Vancomycin Pharmacokinetic and Pharmacodynamic Models for Critically Ill Patients with Post-Sternotomy Mediastinitis

Clinical Pharmacokinetics

Volumn 53, Issue 9, 2014, Pages 849-861

  Mangin, Olivier ^a   Urien, Saïk ^b   Mainardi, Jean Luc ^a   Fagon, Jean Yves ^a   Faisy, Christophe ^a  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; VANCOMYCIN; ANTIINFECTIVE AGENT;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CASE REPORT; CATHETER; COHORT ANALYSIS; CREATININE BLOOD LEVEL; CRITICALLY ILL PATIENT; DIABETES MELLITUS; DISEASE SEVERITY; DRUG CLEARANCE; FEMALE; HUMAN; INTENSIVE CARE UNIT; MALE; MEDIASTINITIS; MINIMUM INHIBITORY CONCENTRATION; MINIMUM PLASMA CONCENTRATION; OBSERVATIONAL STUDY; PHARMACODYNAMICS; PLASMA CONCENTRATION-TIME CURVE; POST STERNOTOMY MEDIASTINITIS; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; SURGICAL DRAINAGE; VERY ELDERLY; VOLUME OF DISTRIBUTION; BIOLOGICAL MODEL; BLOOD; CRITICAL ILLNESS; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; STERNOTOMY;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; COHORT STUDIES; CREATININE; CRITICAL ILLNESS; FEMALE; HUMANS; MALE; MEDIASTINITIS; MIDDLE AGED; MODELS, BIOLOGICAL; POSTOPERATIVE COMPLICATIONS; STERNOTOMY; VANCOMYCIN;

EID: 84920986164     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.1007/s40262-014-0164-z     Document Type: Article

References (40)

1. De Feo M, Renzulli A, Ismeno G, et al. Variables predicting adverse outcome in patients with deep sternal wound infection. Ann Thorac Surg. 2001;71:324–31.
2. Gårdlund B, Bitkover CY, Vaage J. Postoperative mediastinitis in cardiac surgery—microbiology and pathogenesis. Eur J Cardiothorac Surg. 2002;21:825–30.
3. Parisian Mediastinitis Study Group. Risk factors for deep sternal wound infection after sternotomy: a prospective, multicenter study. J Thorac Cardiovasc Surg. 1996;111:1200–7.
4. Fariñas MC, Gald Peralta F, Bernal JM, et al. Suppurative mediastinitis after open-heart surgery: a case–control study covering a seven-year period in Santander, Spain. Clin Infect Dis. 1995;20:272–9.
5. Milano CA, Kesler K, Archibald N, et al. Mediastinitis after coronary artery bypass graft surgery. Risk factors and long-term survival. Circulation. 1995;15:2245–51.
6. Muñoz P, Menasalvas A, Bernaldo de Quirós JC, et al. Postsurgical mediastinitis: a case–control study. Clin Infect Dis. 1997;25:1060–4.
7. Upton A, Roberts SA, Milsom P, et al. Staphylococcal post-sternotomy mediastinitis: five year audit. ANZ J Surg. 2005;75:198–203.
8. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52:1–38.
9. Rybak MJ, Lomaestro BM, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adults summary of consensus recommendations from the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Pharmacotherapy. 2009;29:1275–9.
10. Nakayama H, Echizen H, Tanaka M, et al. Reduced vancomycin clearance despite unchanged creatinine clearance in patients treated with vancomycin for longer than 4 weeks. Ther Drug Monit. 2008;30:103–7.
11. Lodise TP, Patel N, Lomaestro BM, et al. Relationship between initial vancomycin concentration–time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis. 2009;49:507–14.
12. Rodvold KA, Blum RA, Fischer JH, et al. Vancomycin pharmacokinetics in patients with various degrees of renal function. Antimicrob Agents Chemother. 1988;32:848–52.
13. Launay-Vacher V, Izzedine H, Mercadal L, et al. Clinical review: use of vancomycin in haemodialysis patients. Crit Care. 2002;6:313–6.
14. Vance-Bryan K, Guay DR, Gilliland SS, et al. Effect of obesity on vancomycin pharmacokinetic parameters as determined by using a Bayesian forecasting technique. Antimicrob Agents Chemother. 1993;37:436–40.
15. Ducharme MP, Slaughter RL, Edwards DJ. Vancomycin pharmacokinetics in a patient population: effect of age, gender, and body weight. Ther Drug Monit. 1994;16:513–8.
16. Del Mar Fernández de Gatta Garcia M, Revilla N, Calvo MV, et al. Pharmacokinetic/pharmacodynamic analysis of vancomycin in ICU patients. Intensive Care Med. 2007;33:279–85.
17. Yamamoto M, Kuzuya T, Baba H, et al. Population pharmacokinetic analysis of vancomycin in patients with Gram-positive infections and the influence of infectious disease type. J Clin Pharm Ther. 2009;34:473–83.
18. Moise-Broder PA, Forrest A, Birmingham MC, et al. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcusaureus lower respiratory tract infections. Clin Pharmacokinet. 2004;43:925–42.
19. Massias L, Dubois C, de Lentdecker P, et al. Penetration of vancomycin in uninfected sternal bone. Antimicrob Agents Chemother. 1992;36:2539–41.
20. Skhirtladze K, Hutschala D, Fleck T, et al. Impaired target site penetration of vancomycin in diabetic patients following cardiac surgery. Antimicrob Agents Chemother. 2006;50:1372–5.
21. El Oakley RM, Wright JE. Postoperative mediastinitis: classification and management. Ann Thorac Surg. 1996;61:1030–6.
22. European Society of Clinical Microbiology and Infectious Diseases. In: European Committee on Antimicrobial Susceptibility Testing (EUCAST). Clinical breakpoints – bacteria (v 4.0). 2014. http://www.eucast.org/clinical_breakpoints. Accessed 8 June 2014.
23. Roberts JA, Taccone FS, Udy AA, et al. Vancomycin dosing in critically ill patients: robust methods for improved continuous-infusion regimens. Antimicrob Agents Chemother. 2001;55:2704–9.
24. Kirsch M, Mekontso-Dessap A, Houel R, et al. Closed drainage using Redon catheters for poststernotomy mediastinitis: results and risk factors for adverse outcome. Ann Thorac Surg. 2001;71:1580–6.
25. Le Gall JR, Lemeshow S, Saulnier F. A new simplified acute physiology score (SAPS II) based on a European/North American multicenter study. JAMA. 1993;270:2957–63.
26. Kondrup J, Rasmussen HH, Hamberg O, et al. Nutritional Risk Screening (NRS 2002): a new method based on an analysis of controlled clinical trials. Clin Nutr. 2003;22:321–36.
27. Kuhn E, Lavielle M. Maximum likelihood estimation in nonlinear mixed effects models. Comput Stat Data Anal. 2005;49:1020–30.
28. Bergstrand M, Hooker AC, Wallin JE, et al. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011;13:143–51.
29. Ihaka R, Gentleman R. R: a language for data analysis and graphics. J Comput Gr Stat. 1996;5:299–314.
30. Fernan de zdeGatta MM, Fruns I, Dominguez-Gil A. Individualizing vancomycin dosing regimens: an evaluation of two pharmacokinetic dosing programs in critically ill patients. Pharmacotherapy. 1994;14:196–201.
31. Pea F, Porreca L, Baraldo M, Furlanut M. High vancomycin dosage regimens required by intensive care unit patients cotreated with drugs to improve haemodynamics following cardiac surgical procedures. J Antimicrob Chemother. 2000;45:329–35.
32. Vos RJ, van Putte BP, Sonker U, et al. Primary closure using Redon drains for the treatment of post-sternotomy mediastinitis. Interact Cardiovasc Thorac Surg. 2014;18:33–7.
33. Fernandez de Gatta MM, Fruns I, Calvo MV, Lanao JM, Dominguez-Gil A. Influence of pharmacokinetic model on vancomycin peak concentration target. Ther Drug Monit. 1996;18:145–8.
34. Durandy Y, Batisse A, Bourel P, et al. Mediastinal infection after cardiac operation. A simple closed technique. J Thorac Cardiovasc Surg. 1989;97:282–5.
35. Kees MG, Wicha SG, Seefeld A, et al. Unbound fraction of vancomycin in intensive care unit patients. J Clin Pharmacol. 2014;54:318–23.
36. Elting LS, Rubenstein EB, Kurtin D, et al. Mississippi mud in the 1990s: risks and outcomes of vancomycin-associated toxicity in general oncology practice. Cancer. 1998;83:2597–607.
37. Pritchard L, Baker C, Leggett J, et al. Increasing vancomycin serum trough concentrations and incidence of nephrotoxicity. Am J Med. 2010;123:1143–9.
38. Chow AW, Azar RM. Glycopeptides and nephrotoxicity. Intensive Care Med. 1994;20:S23–9.
39. Elyasi S, Khalili H, Hatamkhani S, et al. Prevention of vancomycin induced nephrotoxicity: a review of preclinical data. Eur J Clin Pharmacol. 2013;69:747–54.
40. Vos RJ, Yilmaz A, Sonker U, et al. Primary closure using Redon drains vs vacuum-assisted closure in post-sternotomy mediastinitis. Eur J Cardiothorac Surg. 2012;42:e53–7.